On April 1, 2026, the FDA approved orforglirpon under the brand name Foundayo to reduce excess body weight and maintain weight reduction long term in: Adults with obesity Adults with overweight and at least one weight-related medical condition Like other GLP-1s for weight loss, orforglipron is also indicated in combination with a reduced-calorie diet and increased physical activity
GLP-1 agonists reduce appetite and slow gastric emptying, which can lead to lower blood sugar levels, especially when combined with other glucose-lowering agents
Theres a newer peptide called PDA, or pentadeca arginate, that has a very similar molecular structure as BPC-157, but instead of it being an acetate, its an arginate essentially just swapping out one amino acid for another
NASO B12 has been shown to be rapidly absorbed and highly effective in the treatment of vitamin B12 deficiency
Es hungerte regelrecht und litt somit an einem Mangel aller Nhr- und Vitalstoffe
Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide